Comparable to the 2020 resolution, Novartis AG’s $25 million 2016 civil resolution While using the SEC concerned improper sponsorships of HCPs to conferences and incorrect payments to HCPs to collect “health-related data.” The reality that Novartis is currently going through a substantially larger—and criminal—resolution for similar misco